MedTrace Logo

Red Light Intervention on Myopic Progression

NCT05203432 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2022-10-12

No results posted yet for this study

Summary

To explore the effectiveness of using repeated low-level red-light therapy to slow myopia progression.

Conditions

  • Myopia

Interventions

DEVICE

Red Light Intervention

Repeated Low-Level Red-Light Therapy

DRUG

Atropine

0.01% atropine

Sponsors & Collaborators

  • Shanghai Eye Disease Prevention and Treatment Center

    lead OTHER

Principal Investigators

  • Jiannan Huang · Shanghai Eye Disease Prevention and Treatment Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05203432 on ClinicalTrials.gov